The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Study critique

Reverse causation in a cohort study of weight and outcome

LV
l.vukovicTL2 Moderator23 Dec 2025#1

On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion.

Comparing SELECT (N Engl J Med, 2023) with FLOW (N Engl J Med, 2024) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

12 likes 7mo
D
DOdendaalTL3Regular25 Dec 2025#2

When you change your mind: if a reply convinces you that your criticism was not well-founded, say so plainly. The critique might still be real but smaller than you originally thought. That is not a failure — it is how discussion works.

16 likes 7mo
RI
r.ilungaTL2 Moderator26 Dec 2025#3

post #2 is right about the mechanism and I think understates the practical bit.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

32 likes 7mo
ED
e.dalgleishTL3Regular26 Dec 2025 · edited#4

Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished negative trials is a fair critical question.

0 likes 7mo
DN
d.nilsenTL2 Moderator27 Dec 2025#5

Multiple comparisons: if a paper reports many outcomes, the chance of a spurious association by random chance is real. Pre-specification of primary outcomes matters and secondary analyses are weaker evidence.

10 likes 7mo
O
OTeixeiraTL3Regular28 Dec 2025#6

Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative statistical analysis might bias toward null.

23 likes 7mo
NZ
n.zielinskiTL2 Moderator29 Dec 2025#7

post #6 answers the question as asked. The question underneath it is different.

Confounding: in observational data, is there a third variable that explains the apparent association? In randomised data, randomisation should balance unknown confounders, though known confounders can be adjusted for.

0 likes 7mo
M
MJayawardenaTL3Regular30 Dec 2025#8
OTeixeira, post #6: Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative statistical analysis might bias toward null. Go to post

On post #4 — agreed on the reasoning, with one qualification.

Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do not apply to real people asking about it? This is a fair criticism but requires specificity about which real people and why the difference matters.

1 like in reply to #6 7mo
ID
il.dumitruTL2 Moderator30 Dec 2025#9
e.dalgleish, post #4: Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished negative trials is a fair critical question. Go to post

This follows post #6 rather than contradicting it.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

1 like in reply to #4 7mo
GH
g.haalandTL3Regular31 Dec 2025#10
n.zielinski, post #7: post #6 answers the question as asked. The question underneath it is different. Confounding: in observational data, is there a third variable that explains the apparent association? In randomised data, randomisation should balance unknown confounders, though known confounders can be adjusted for. Go to post

I read post #8 twice before replying, because I had assumed the opposite.

Choosing the worst interpretation: "The confidence interval includes a harmful effect" is true if the CI goes from -1 to +5. But assuming the worst-case scenario is not how you use the evidence. The point estimate and the precision both matter.

7 likes in reply to #7 7mo
PO
p.onwukaTL2 Moderator1 Jan 2026#11
d.nilsen, post #5: Multiple comparisons: if a paper reports many outcomes, the chance of a spurious association by random chance is real. Pre-specification of primary outcomes matters and secondary analyses are weaker evidence. Go to post

Building consensus on which criticisms matter: if everyone agrees that the sample size is small but only you think that affects the conclusion, maybe your criticism is more idiosyncratic. That does not make it wrong but it is worth noticing.

0 likes in reply to #5 7mo
HN
h.nicolaidesTL3Regular1 Jan 2026#12
r.ilunga, post #3: post #2 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up. Go to post

Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question. Sometimes that is what the sponsor wanted, sometimes the researchers did the best they could with constraints.

32 likes in reply to #3 7mo
DN
d.ndiayeTL2 Moderator2 Jan 2026#13

I read post #11 twice before replying, because I had assumed the opposite.

What makes a methodological criticism substantive: it identifies a specific feature of the design that materially affects what the paper can conclude. "Small sample size" alone is weak. "Small sample size for a rare outcome, so the confidence interval is wide" is stronger.

11 likes 7mo
LA
l.aaltonenTL3Regular3 Jan 2026#14

This follows post #11 rather than contradicting it.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

3 likes 7mo
MD
m.dumitruTL2 Moderator3 Jan 2026#15

Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do not apply to real people asking about it? This is a fair criticism but requires specificity about which real people and why the difference matters.

0 likes 7mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…
LHCKSVCW+117 129 45k 5mo
Coming back to: A structured critique template this community uses
Posting this under the heading it deserves: A structured critique template this community uses Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med , 2022)…
SOFAKHASMY+63 69 17k 18h
A structured critique template this community uses
A structured critique template this community uses — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…
ZOCEK 2 18k 1d
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim…
KBZOKOJMTV+55 61 60k 15mo
A claim built entirely on a subgroup analysis
A claim built entirely on a subgroup analysis Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support of a claim I do…
ASKHMIASNP+71 80 1.1k 14mo

Related topics — sharing the tags disputed, observational data, effect size

TopicParticipantsRepliesViewsActivity
The retatrutide phase 2 obesity paper, read closely
Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…
KTDEF 2 65k 10mo
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with SURMOUNT-4 ( JAMA , 2024) and…
AKACRIGKR+103 110 8.1k 2h
Sample size intuition for a personal experiment
On the subject in the title: Sample size intuition for a personal experiment Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is…
RKHECAHTT 4 62k 18mo
What TRIUMPH is designed to answer, and why we should not pre-empt it
What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…
NNRNCIHBEK+4 8 142 6h
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…
SBKRSICPMN+27 31 1.2k 22h